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Background: MicroRNA-126(miR-126) has been shown to be frequently down-regulated in a variety of malignancies
and act as a potential tumor suppressor. However, its correlations with the clinicopathological characters of cervical
cancer remain unclear.
Methods: TaqMan quantitative RT-PCR was used to determine the expression level of miR-126 in tissue samples. The
associations of miR-126 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis
was performed to analyze the association of miR-126 expression with overall survival (OS) of patients. Univariate
and multivariate Cox regression analyses were performed.
Results: miR-126 expression level in human cervical cancer tissues was significantly lower than that in adjacent
nontumorous tissues (mean ± SD: 0.59 ± 0.44 vs. 1.00 ± 0.51, P < 0.0001). Decreased miR-126 expression in cervical
cancer was found to be significantly associated with lymphatic invasion (P = 0.002), distant metastasis (P < 0.001),
FIGO stage (P = 0.009), and histological grade (P = 0.005). Kaplan-Meier analysis showed that patients with lower
levels of miR-126 had significantly poorer survival than those with higher expression of this miRNA in patients, with
a 5-year OS of 45.7% and 70.9%, respectively (P = 0.002). Multivariate analysis revealed that miR-126 expression
(HR = 3.97, 95% CI: 2.01-20.22; P = 0.003) was independently associated with the OS.
Conclusion: Our data suggests the potential of miR-126 as a prognostic biomarker for cervical cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_220
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Cervical cancer is the second leading cause of death
among women worldwide, with an estimated 530,000
deaths per year [1]. Although radiotherapy, chemotherapy
and surgery have been recently used as standard treatment
modalities for patients with cervical cancer, with conse-
quent disease remission, clinical outcomes vary signifi-
cantly between patients and can be difficult to predict.
Therefore, it is important to understand the complete
knowledge of the molecular biology, genetics, causes and
cellular origin of cervical cancers which are of value in the* Correspondence: qingdao_chenlong@126.com
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unless otherwise stated.development of improved therapeutic strategies and in the
identification of prognostic markers [2].
MicroRNAs (miRNAs) are small, conserved, non-
coding short RNAs of 18–25 nucleotides in length that
bind to target mRNAs mainly at their 3’-untranslated re-
gion (UTR) [3]. Many miRNAs have been implicated as
key regulators of cellular growth and differentiation and
have been found to deregulate proliferation in human
cancers [4-6]. In human cancers, the expression of
miRNAs is generally down-regulated or up-regulated
in malignant tissues compared with the corresponding
nonmalignant tissues, suggesting the deregulation of
miRNA expression and the contribution of miRNAs to
the multistep processes of carcinogenesis, either as
oncogenes or as tumor-suppressor genes [7-9].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The relationship between miR-126 expression






Low High P value
Age (y)
<65 56 29 27 0.46
≥ 65 77 33 44
HPV
(+) 97 47 50 0.21
(−) 36 15 21
Tumor histology
Squamous 101 54 47 0.19
Adenocarcinoma 22 5 17
Clear cell 10 3 7
Tumor Size (cm)
<4 54 19 35 0.07
≥4 79 43 36
Lymphatic invasion
Yes 63 45 18 0.002
No 70 17 53
Distant metastasis
Yes 28 23 5 <0.001
No 105 39 66
FIGO stage
I/II 62 20 42 0.009
III/IV 71 42 29
Histological grade
Well/moderate 82 25 57 0.005
Poor 51 37 14
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malignancies and acts as a potential tumor suppressor
[10-12]. Moreover, low expression of miR-126 has been
found to be correlated with poor prognosis in patients
with breast cancer, adult T cell leukemia, colorectal can-
cer(CRC) and malignant mesothelioma [13-15]. Previ-
ously, miR-126 expression level in cervical cancer tissues
was found to be significantly decreased compared with
that in normal cervical tissues (P <0.01). However, the
clinical significance and prognostic value of miR-126 in
cervical cancer have not been investigated.
Methods
Patients and tissue samples
Fresh cervical cancer and matched adjacent normal
tissue specimens were collected from 133 patients who
underwent surgery between March 2008 and July 2013
in the Department of Gynecology, Qingdao Municipal
Hospital. The corresponding adjacent normal tissues
were obtained 3 cm beyond the boundary of cervical
cancer tissues. The fresh tissue specimens were immedi-
ately frozen in liquid nitrogen until use. The selection
criteria for patients with cervical cancer were as follows:
(1) pathologically confirmed patients with cervical can-
cer; (2) the patients had no history of other cancers. No
patients had preoperative chemotherapy, radiotherapy,
or other treatment history or other inflammatory dis-
eases. Patient’s conditions were staged according to the
criteria of the International Federation of Gynecology
and Obstetrics (FIGO). The clinicopathologic features of
all the patients were summarized in Table 1. Overall sur-
vival(OS) time was calculated from the date of the initial
surgical operation to death. Follow-up information of all
patients was updated every 3 months for the first 2 years,
every 4 months for the third year, every 6 months for
the fourth and fifth years, and then every year thereafter
by telephone visit and questionnaire letters. Death of the
participants was ascertained by reporting from the fam-
ily and verified by review of public records.
This study was approved by the Research Ethics
Committee of the Qingdao Municipal Hospital. Written
informed consent was obtained from all of the patients.
All specimens were handled and made anonymous
according to the ethical and legal standards.
RNA extraction and Real-Time RT-PCR
Total RNA was extracted with Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The concentration and purity of all
RNA samples were detected by NanoDrop ND-2000
spectrophotometer (NanoDrop Technologies, Houston,
TX, USA). NCode™ SYBR® Green miRNA qRT-PCR Kit
(Invitrogen, Carlsbad, CA, USA) was used to synthesize
specific cDNA of miR-126 and U6B(as an internalcontrol), and perform qRT-PCR, which was analyzed
with the DNA Engine Opticon 2 Real-Time Cycler (MJ
Research Inc., Waltham, MA, USA) according to the
manufacturer’s instructions. Each sample was examined
in triplicate and analyzed by the comparative threshold
cycle (Ct) method. The expression levels of miR-126
were normalized to U6B.
Statistical analysis
Statistical analysis was conducted using the SPSS 18.0
for Windows (SPSS Inc., Chicago, IL, USA). The chi-
square test was used to assess miR-126 expression with
respect to clinicopathological parameters. The survival
curves of the patients were determined using the
Kaplan-Meier method and Cox regression, and the log-
rank test was used for statistical evaluations. Univariate
Cox regression was performed on each clinical covariate
to examine its influence on patient survival. Final
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Wald statistic of P < 0.05 was used as the criterion for
inclusion in final multivariate models. Data were
expressed as the mean and standard deviation and ana-
lyzed using one-way analysis of variance. P < 0.05 was
considered to indicate a significant difference.Results
The expression level of miR-126 in cervical cancer
qRT-PCR was used to assess the expression of miR-126
in cervical cancer tissues and adjacent non-tumorous
tissues. The results showed that miR-126 expression
level in human cervical cancer tissues was significantly
lower than that in adjacent nontumorous tissues
(mean ± SD: 0.59 ± 0.44 vs. 1.00 ± 0.51, P < 0.0001;
shown in Figure 1).Correlation of miR-126 expression with clinicopathological
characteristics
The Median expression level of miR-126 was used as a
cut-off point to divide all 133 patients into two groups:
cervical cancer patients who expressed miR-126 at levels
less than the cut-off value were assigned to the low ex-
pression group (n =62), and those with expression above
the cut-off value were assigned to the high expression
group (n =71). The relationships between miR-126 ex-
pression levels and different clinicopathological factors
were shown in Table 1. Decreased miR-126 expression
in cervical cancer was found to be significantly associ-
ated with lymphatic invasion (P = 0.002), distant metas-
tasis (P < 0.001), FIGO stage (P = 0.009), and histological
grade (P = 0.005). However, no significant correlation
was observed between miR-126 expression and other
clinicopathologic variables, such as age, HPV infection,
tumor histology, and tumor size (all P > 0.05).Figure 1 miR-126 expression levels in cervical cancer tissues
and adjacent non-tumorous tissues. miR-126 expression in cervical
cancer tissues was significantly lower than that in adjacent nontumorous
tissues (mean ± SD: 0.59 ± 0.44 vs. 1.00 ± 0.51, P < 0.0001).Relationship between miR-126 expression and cervical
cancer patients’ survival
To evaluate whether miR-126 expression can predict
cervical cancer prognosis, we next performed survival
analysis. Kaplan-Meier analysis showed that patients
with lower levels of miR-126 had significantly poorer
survival than those with higher expression of this
miRNA in patients, with a 5-year OS of 45.7% and
70.9%, respectively(P = 0.002; shown in Figure 2).
Univariate and multivariate analyses were utilized to
evaluate whether the miR-126 expression level and vari-
ous clinicopathological features were independent prog-
nostic parameters of patient outcomes. Multivariate
analysis revealed that miR-126 expression (HR = 3.97,
95% CI: 2.01-20.22; P = 0.003), distant metastasis (HR =
4.78, 95% CI: 2.31-20.12; P = 0.004), and FIGO stage
(HR = 2.12, 95% CI: 1.68-18.29; P = 0.001) were inde-
pendently associated with the overall survival (shown in
Table 2).
Discussion
Accurate prediction of the prognosis for the individual
patient with cervical cancer is of great importance, and
molecular biomarkers that could be served as prognostic
markers would be useful in determining an individual-
ized treatment plan for a cervical cancer patient. How-
ever, the biomarkers used in this tumor group today are
not satisfactory, and it is needed to exploit additional
markers to fine-tune this process.
MiRNAs, a class of naturally occurring, non-coding,
short single stranded RNAs, are deregulated in cancer,
and they are involved in malignant transformation and
tumor development. In recent years, numerous studies
have shown aberrant expression of miRNAs in human
cancers, including cervical cancer, some of which func-
tion as tumor suppressor genes or oncogenes. Due to
their tissue-and disease-specific expression patterns and
tremendous regulatory potential, miRNAs are being
identified as diagnostic and prognostic biomarkers, as
well as additional therapeutic tools [16,17]. As more and
more studies report the relationships between miRNAs
and cervical cancer, its potential as novel biomarkers in
cervical cancer is growing [18-20].
MiR-126, derived from a common precursor structure
located within the epidermal growth factor-like domain
7 (EGFL7) gene, is frequently down-regulated in a
variety of malignancies and acts as a potential tumor
suppressor [10-12]. Previous studies have reported that
miR-126 may play a role in tumorigenesis and growth
by regulating the vascular endothelial growth factor
(VEGF)/phosphoinositol 3-kinase (PI3K)/AKT signaling
pathways in human breast cancer [21]. Additionally, this
miRNA may function as a tumor suppressor, with Crk
as a direct target, in gastric cancer [22] and via the
Figure 2 Survival analysis of the miR-126 expression levels with overall survival of patients with cervical cancer after surgery.
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126 may also play a role in angiogenesis in ischemia
[24], and has also been reported to enhance the sensitiv-
ity of non-small cell lung cancer(NSCLC) cells to anti-
cancer agents by targeting VEGF-A [25]. Together, these
previous studies have demonstrated the important role
of miR-126 in various cancers. Moreover, low expression
of miR-126 has been found to be correlated with poor
prognosis in patients with breast cancer, adult T cell
leukemia, CRC and malignant mesothelioma [13-15].
Previously, miR-126 expression in cervical cancer tissuesTable 2 Multivariate Cox’s hazards model analysis for
prognostic factors
Variable Hazard ratio 95% CI P value
Age (y) 1.02 0.29-2.88 0.66
HPV 1.28 0.79-2.44 0.11
Tumor Size (cm) 2.11 0.81-3.19 0.09
Tumor histology 0.91 0.25-1.91 0.81
Lymphatic invasion 3.14 0.88-19.23 0.06
Distant metastasis 4.78 2.31-20.12 0.004
FIGO stage 2.12 1.68-18.29 0.001
Histological grade 5.11 0.91-17.89 0.07
miR-126 expression 3.97 2.01-20.22 0.003was found to be significantly decreased compared with
that in normal cervical tissues. Yu et al. found that miR-
126 was able to suppress the proliferation of cervical
cancer cells and alters cell sensitivity to the chemothera-
peutic drug bleomycin [26]. However, the clinical signifi-
cance and prognostic value of miR-126 in cervical
cancer have not been investigated. In the present study,
we showed that miR-126 was significantly down-
regulated in cervical cancer tissues for the first time. De-
creased miR-126 expression in cervical cancer was found
to be significantly associated with lymphatic invasion,
distant metastasis, FIGO stage, and histological grade,
suggesting that miR-126 might be involved in the car-
cinogenesis and metastasis of cervical cancer. More
importantly, we proved that patients with a lower ex-
pression of miR-126 tended to have shorter survival than
patients with higher levels. Furthermore, multivariate
analysis revealed that miR-126 expression was independ-
ently associated with the OS, indicating that lower miR-
126 level was a marker of poor prognosis for patients
with cervical cancer.
Conclusions
In conclusion, this study indicated that down-regulation
miR-126 was associated with tumor progression and
poor prognosis in cervical cancer and was identified for
Yang et al. Diagnostic Pathology  (2014) 9:220 Page 5 of 5the first time as an independent poor prognostic factor
for patients with cervical cancer. Further study with a
larger case population is needed to confirm the prognos-
tic value of miR126 expression in cervical cancer.
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